Výsledky vyhledávání - "Talmasson, G"

Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults

Autor: Garau, J, Twynholm, M, Garcia Mendez, E, Siquier, B, Rivero, A, 557 Clinical Study Group, Aguilar, L, Almirante, B, Blanquer, R, Bouza, E, Caminero, J, Custardoy, J, De la Torre, J, Fernández Funcia, M, Gil, A, Gomez, J, Gómez, L, Juárez, S, Llorca, E, Molinos, L, Moreno, S, Muniain, Ma, Pachón, J, Pallarés, R, Pascual, M, Sánchez, J, Santos, J, Vidal, J, Viejo, Jl, Zubillaga, G, Beghi, G, Cacciani, S, Cattaneo, C, Cogo, R, Concia, Ercole, Dal Negro, R, Giosue, S, Giuntini, C, Raineri, M, Sutti, F, Talmasson, G, Tassi, G, Todisco, T, Richard, Mp

Publikováno v: The Journal of antimicrobial chemotherapy. 52(5)

Objectives Pharmacokinetically enhanced co-amoxiclav 2000/125 mg was designed to achieve high serum concentrations of amoxicillin over the 12 h dosing interval to eradicate Streptococcus pneumoniae with amoxicillin MICs of at least 4 mg/L. Methods Th

Vyhledávací nástroje:

Upřesnit hledání